100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R41DA049615
Award Date
7/1/20
Completion Date
6/30/21
Dollars Obligated
$390K
Overview
Activity
5
Transactions
5
Subawards
Similar Awards
Federal Agency
National Institute on Drug Abuse
Awardee
Rekovar Inc. (EJX5YKMCKG35)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Update #1
Update #2
WIRELESS WITHDRAWAL DETECTION AND MONITORING SYSTEM FOR NEONATAL ABSTINENCE SYNDROME.
Posted 6/23/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
WIRELESS WITHDRAWAL DETECTION AND MONITORING SYSTEM FOR NEONATAL ABSTINENCE SYNDROME. - SPECIFIC AIMS NEONATAL ABSTINENCE SYNDROME (NAS) IS AN OPIOID WITHDRAWAL SYNDROME THAT DEVELOPS SHORTLY AFTER BIRTH TO IN UTERO-EXPOSED NEONATES. THE COST OF NAS IS HIGH: NEWBORNS WITH NAS ARE TYPICALLY RECEIVE CARE IN THE NEONATAL INTENSIVE CARE UNIT (NICU), WHERE THE DAILY COST OF CARE IS HIGH. NEARLY 22,000 INFANTS ARE BORN WITH NAS EACH YEAR AT A COST OF $1.5 BILLION. MOREOVER, MEDICATION-BASED INTERVENTIONS FOR THE TREATMENT OF NAS, USED IN UP TO 80% OF OPIOID-EXPOSED INFANTS, CARRY THEIR OWN RISKS OF TOXICITY AND DRUG INTERACTIONS. DESPITE THE MEDICAL COST, HIGH SOCIETAL IMPACT OF NAS, AND THE RISKS OF TREATMENT, THE TOOLS TO ASSESS THE SEVERITY OF NAS CAN BE SUBJECTIVE AND SUFFER FROM EXAMINER BIAS. THERE IS AN URGENT NEED FOR INNOVATIVE NEW METHODS TO DIAGNOSE NAS AND ASSESS THE EFFICACY OF RESPONSES TO TREATMENT. FLEXIBLE, LOW-COST WEARABLE DEVICES (WORN ON THE SKIN) THAT CAN REPORT MEASURES OF SYSTEMIC BIOCHEMICAL AND BIOMECHANICAL PROCESSES OFFER A SIMPLE AND ECONOMICAL SOLUTION. IN NAS, SURGES OF SYMPATHETIC NERVOUS SYSTEM ACTIVITY PRODUCE INCREASED HEART RATE, SKIN CONDUCTANCE, UNSTABLE TEMPERATURE, AND TREMOR. THESE MANIFEST IN INCREASED INFANT SWEATING, SEIZURES, TREMORS, UNSTABLE BODY TEMPERATURE, AND MORE-EVENTS THAT MUST CONTINUALLY MONITORED AND ASSESSED BY NURSES. THE UNSUPERVISED, OBJECTIVE DETECTION/QUANTIFICATION OF THE BODILY RESPONSE OF NEONATES SUFFERING FROM NAS COULD DRIVE THE DEVELOPMENT OF NEW, OBJECTIVE SCORING TOOLS THAT CAN GUIDE THE INITIATION, INTENSITY, AND DURATION OF THERAPIES FOR NAS. SUCH TOOLS COULD SIGNIFICANTLY REDUCE MEDICAL COSTS AND IMPROVE PATIENT OUTCOMES BY REDUCING PATIENT TIME IN NICU, REDUCING NURSE LOAD, IMPROVING OUTPATIENT MONITORING, AND HELPING TO ASSIST IN THE OPTIMIZATION OF PATIENT TREATMENTS. CRITICALLY, WE BELIEVE SUCH A TOOL MAY BE ABLE TO OBJECTIVELY CAPTURE EVENTS THAT MAY GO UNNOTICED BY NURSES OR WHILE THE INFANT IS SLEEPING (MINOR TREMORS, POOR OXYGENATION, TEMPERATURE FLUCTUATIONS, DEHYDRATION). THIS PROPOSAL SEEKS TO DEVELOP INTERLINKED, INFANT-TARGETED WEARABLE BIOSENSOR-SYSTEMS CAPABLE OF CONTINUOUSLY MONITORING THE BIOCHEMICAL TO BIOPHYSICAL PARAMETERS OF OPIOID-DEPENDENT NEONATES UNDER TREATMENT FOR NAS. OUR TEAM HAS OUTSTANDING EXPERIENCE IN ALL AREAS NECESSARY TO THIS INVESTIGATION. OUR BUSINESS UNIT HAS EXTENSIVE NIH FUNDED EXPERIENCE IN WEARABLE BIOSENSING, IN THE DETECTION OF SYMPATHETIC NERVOUS SYSTEM ACTIVITY IN OPIOID WITHDRAWAL, PEDIATRICS, BUSINESS DEVELOPMENT, AND INTELLECTUAL PROPERTY. OUR ACADEMIC PARTNERS HAVE BROAD EXPERIENCE IN NOVEL BIOSENSOR DEVELOPMENT.
$0
5/13/22
Not listed
WIRELESS WITHDRAWAL DETECTION AND MONITORING SYSTEM FOR NEONATAL ABSTINENCE SYNDROME. - SPECIFIC AIMS NEONATAL ABSTINENCE SYNDROME (NAS) IS AN OPIOID WITHDRAWAL SYNDROME THAT DEVELOPS SHORTLY AFTER BIRTH TO IN UTERO-EXPOSED NEONATES. THE COST OF NAS IS HIGH: NEWBORNS WITH NAS ARE TYPICALLY RECEIVE CARE IN THE NEONATAL INTENSIVE CARE UNIT (NICU), WHERE THE DAILY COST OF CARE IS HIGH. NEARLY 22,000 INFANTS ARE BORN WITH NAS EACH YEAR AT A COST OF $1.5 BILLION. MOREOVER, MEDICATION-BASED INTERVENTIONS FOR THE TREATMENT OF NAS, USED IN UP TO 80% OF OPIOID-EXPOSED INFANTS, CARRY THEIR OWN RISKS OF TOXICITY AND DRUG INTERACTIONS. DESPITE THE MEDICAL COST, HIGH SOCIETAL IMPACT OF NAS, AND THE RISKS OF TREATMENT, THE TOOLS TO ASSESS THE SEVERITY OF NAS CAN BE SUBJECTIVE AND SUFFER FROM EXAMINER BIAS. THERE IS AN URGENT NEED FOR INNOVATIVE NEW METHODS TO DIAGNOSE NAS AND ASSESS THE EFFICACY OF RESPONSES TO TREATMENT. FLEXIBLE, LOW-COST WEARABLE DEVICES (WORN ON THE SKIN) THAT CAN REPORT MEASURES OF SYSTEMIC BIOCHEMICAL AND BIOMECHANICAL PROCESSES OFFER A SIMPLE AND ECONOMICAL SOLUTION. IN NAS, SURGES OF SYMPATHETIC NERVOUS SYSTEM ACTIVITY PRODUCE INCREASED HEART RATE, SKIN CONDUCTANCE, UNSTABLE TEMPERATURE, AND TREMOR. THESE MANIFEST IN INCREASED INFANT SWEATING, SEIZURES, TREMORS, UNSTABLE BODY TEMPERATURE, AND MORE-EVENTS THAT MUST CONTINUALLY MONITORED AND ASSESSED BY NURSES. THE UNSUPERVISED, OBJECTIVE DETECTION/QUANTIFICATION OF THE BODILY RESPONSE OF NEONATES SUFFERING FROM NAS COULD DRIVE THE DEVELOPMENT OF NEW, OBJECTIVE SCORING TOOLS THAT CAN GUIDE THE INITIATION, INTENSITY, AND DURATION OF THERAPIES FOR NAS. SUCH TOOLS COULD SIGNIFICANTLY REDUCE MEDICAL COSTS AND IMPROVE PATIENT OUTCOMES BY REDUCING PATIENT TIME IN NICU, REDUCING NURSE LOAD, IMPROVING OUTPATIENT MONITORING, AND HELPING TO ASSIST IN THE OPTIMIZATION OF PATIENT TREATMENTS. CRITICALLY, WE BELIEVE SUCH A TOOL MAY BE ABLE TO OBJECTIVELY CAPTURE EVENTS THAT MAY GO UNNOTICED BY NURSES OR WHILE THE INFANT IS SLEEPING (MINOR TREMORS, POOR OXYGENATION, TEMPERATURE FLUCTUATIONS, DEHYDRATION). THIS PROPOSAL SEEKS TO DEVELOP INTERLINKED, INFANT-TARGETED WEARABLE BIOSENSOR-SYSTEMS CAPABLE OF CONTINUOUSLY MONITORING THE BIOCHEMICAL TO BIOPHYSICAL PARAMETERS OF OPIOID-DEPENDENT NEONATES UNDER TREATMENT FOR NAS. OUR TEAM HAS OUTSTANDING EXPERIENCE IN ALL AREAS NECESSARY TO THIS INVESTIGATION. OUR BUSINESS UNIT HAS EXTENSIVE NIH FUNDED EXPERIENCE IN WEARABLE BIOSENSING, IN THE DETECTION OF SYMPATHETIC NERVOUS SYSTEM ACTIVITY IN OPIOID WITHDRAWAL, PEDIATRICS, BUSINESS DEVELOPMENT, AND INTELLECTUAL PROPERTY. OUR ACADEMIC PARTNERS HAVE BROAD EXPERIENCE IN NOVEL BIOSENSOR DEVELOPMENT.
$0
5/13/22
Not listed
WIRELESS WITHDRAWAL DETECTION AND MONITORING SYSTEM FOR NEONATAL ABSTINENCE SYNDROME. - SPECIFIC AIMS NEONATAL ABSTINENCE SYNDROME (NAS) IS AN OPIOID WITHDRAWAL SYNDROME THAT DEVELOPS SHORTLY AFTER BIRTH TO IN UTERO-EXPOSED NEONATES. THE COST OF NAS IS HIGH: NEWBORNS WITH NAS ARE TYPICALLY RECEIVE CARE IN THE NEONATAL INTENSIVE CARE UNIT (NICU), WHERE THE DAILY COST OF CARE IS HIGH. NEARLY 22,000 INFANTS ARE BORN WITH NAS EACH YEAR AT A COST OF $1.5 BILLION. MOREOVER, MEDICATION-BASED INTERVENTIONS FOR THE TREATMENT OF NAS, USED IN UP TO 80% OF OPIOID-EXPOSED INFANTS, CARRY THEIR OWN RISKS OF TOXICITY AND DRUG INTERACTIONS. DESPITE THE MEDICAL COST, HIGH SOCIETAL IMPACT OF NAS, AND THE RISKS OF TREATMENT, THE TOOLS TO ASSESS THE SEVERITY OF NAS CAN BE SUBJECTIVE AND SUFFER FROM EXAMINER BIAS. THERE IS AN URGENT NEED FOR INNOVATIVE NEW METHODS TO DIAGNOSE NAS AND ASSESS THE EFFICACY OF RESPONSES TO TREATMENT. FLEXIBLE, LOW-COST WEARABLE DEVICES (WORN ON THE SKIN) THAT CAN REPORT MEASURES OF SYSTEMIC BIOCHEMICAL AND BIOMECHANICAL PROCESSES OFFER A SIMPLE AND ECONOMICAL SOLUTION. IN NAS, SURGES OF SYMPATHETIC NERVOUS SYSTEM ACTIVITY PRODUCE INCREASED HEART RATE, SKIN CONDUCTANCE, UNSTABLE TEMPERATURE, AND TREMOR. THESE MANIFEST IN INCREASED INFANT SWEATING, SEIZURES, TREMORS, UNSTABLE BODY TEMPERATURE, AND MORE-EVENTS THAT MUST CONTINUALLY MONITORED AND ASSESSED BY NURSES. THE UNSUPERVISED, OBJECTIVE DETECTION/QUANTIFICATION OF THE BODILY RESPONSE OF NEONATES SUFFERING FROM NAS COULD DRIVE THE DEVELOPMENT OF NEW, OBJECTIVE SCORING TOOLS THAT CAN GUIDE THE INITIATION, INTENSITY, AND DURATION OF THERAPIES FOR NAS. SUCH TOOLS COULD SIGNIFICANTLY REDUCE MEDICAL COSTS AND IMPROVE PATIENT OUTCOMES BY REDUCING PATIENT TIME IN NICU, REDUCING NURSE LOAD, IMPROVING OUTPATIENT MONITORING, AND HELPING TO ASSIST IN THE OPTIMIZATION OF PATIENT TREATMENTS. CRITICALLY, WE BELIEVE SUCH A TOOL MAY BE ABLE TO OBJECTIVELY CAPTURE EVENTS THAT MAY GO UNNOTICED BY NURSES OR WHILE THE INFANT IS SLEEPING (MINOR TREMORS, POOR OXYGENATION, TEMPERATURE FLUCTUATIONS, DEHYDRATION). THIS PROPOSAL SEEKS TO DEVELOP INTERLINKED, INFANT-TARGETED WEARABLE BIOSENSOR-SYSTEMS CAPABLE OF CONTINUOUSLY MONITORING THE BIOCHEMICAL TO BIOPHYSICAL PARAMETERS OF OPIOID-DEPENDENT NEONATES UNDER TREATMENT FOR NAS. OUR TEAM HAS OUTSTANDING EXPERIENCE IN ALL AREAS NECESSARY TO THIS INVESTIGATION. OUR BUSINESS UNIT HAS EXTENSIVE NIH FUNDED EXPERIENCE IN WEARABLE BIOSENSING, IN THE DETECTION OF SYMPATHETIC NERVOUS SYSTEM ACTIVITY IN OPIOID WITHDRAWAL, PEDIATRICS, BUSINESS DEVELOPMENT, AND INTELLECTUAL PROPERTY. OUR ACADEMIC PARTNERS HAVE BROAD EXPERIENCE IN NOVEL BIOSENSOR DEVELOPMENT.
$55.0k
2/18/21
Not listed
WIRELESS WITHDRAWAL DETECTION AND MONITORING SYSTEM FOR NEONATAL ABSTINENCE SYNDROME. - SPECIFIC AIMS NEONATAL ABSTINENCE SYNDROME (NAS) IS AN OPIOID WITHDRAWAL SYNDROME THAT DEVELOPS SHORTLY AFTER BIRTH TO IN UTERO-EXPOSED NEONATES. THE COST OF NAS IS HIGH: NEWBORNS WITH NAS ARE TYPICALLY RECEIVE CARE IN THE NEONATAL INTENSIVE CARE UNIT (NICU), WHERE THE DAILY COST OF CARE IS HIGH. NEARLY 22,000 INFANTS ARE BORN WITH NAS EACH YEAR AT A COST OF $1.5 BILLION. MOREOVER, MEDICATION-BASED INTERVENTIONS FOR THE TREATMENT OF NAS, USED IN UP TO 80% OF OPIOID-EXPOSED INFANTS, CARRY THEIR OWN RISKS OF TOXICITY AND DRUG INTERACTIONS. DESPITE THE MEDICAL COST, HIGH SOCIETAL IMPACT OF NAS, AND THE RISKS OF TREATMENT, THE TOOLS TO ASSESS THE SEVERITY OF NAS CAN BE SUBJECTIVE AND SUFFER FROM EXAMINER BIAS. THERE IS AN URGENT NEED FOR INNOVATIVE NEW METHODS TO DIAGNOSE NAS AND ASSESS THE EFFICACY OF RESPONSES TO TREATMENT. FLEXIBLE, LOW-COST WEARABLE DEVICES (WORN ON THE SKIN) THAT CAN REPORT MEASURES OF SYSTEMIC BIOCHEMICAL AND BIOMECHANICAL PROCESSES OFFER A SIMPLE AND ECONOMICAL SOLUTION. IN NAS, SURGES OF SYMPATHETIC NERVOUS SYSTEM ACTIVITY PRODUCE INCREASED HEART RATE, SKIN CONDUCTANCE, UNSTABLE TEMPERATURE, AND TREMOR. THESE MANIFEST IN INCREASED INFANT SWEATING, SEIZURES, TREMORS, UNSTABLE BODY TEMPERATURE, AND MORE-EVENTS THAT MUST CONTINUALLY MONITORED AND ASSESSED BY NURSES. THE UNSUPERVISED, OBJECTIVE DETECTION/QUANTIFICATION OF THE BODILY RESPONSE OF NEONATES SUFFERING FROM NAS COULD DRIVE THE DEVELOPMENT OF NEW, OBJECTIVE SCORING TOOLS THAT CAN GUIDE THE INITIATION, INTENSITY, AND DURATION OF THERAPIES FOR NAS. SUCH TOOLS COULD SIGNIFICANTLY REDUCE MEDICAL COSTS AND IMPROVE PATIENT OUTCOMES BY REDUCING PATIENT TIME IN NICU, REDUCING NURSE LOAD, IMPROVING OUTPATIENT MONITORING, AND HELPING TO ASSIST IN THE OPTIMIZATION OF PATIENT TREATMENTS. CRITICALLY, WE BELIEVE SUCH A TOOL MAY BE ABLE TO OBJECTIVELY CAPTURE EVENTS THAT MAY GO UNNOTICED BY NURSES OR WHILE THE INFANT IS SLEEPING (MINOR TREMORS, POOR OXYGENATION, TEMPERATURE FLUCTUATIONS, DEHYDRATION). THIS PROPOSAL SEEKS TO DEVELOP INTERLINKED, INFANT-TARGETED WEARABLE BIOSENSOR-SYSTEMS CAPABLE OF CONTINUOUSLY MONITORING THE BIOCHEMICAL TO BIOPHYSICAL PARAMETERS OF OPIOID-DEPENDENT NEONATES UNDER TREATMENT FOR NAS. OUR TEAM HAS OUTSTANDING EXPERIENCE IN ALL AREAS NECESSARY TO THIS INVESTIGATION. OUR BUSINESS UNIT HAS EXTENSIVE NIH FUNDED EXPERIENCE IN WEARABLE BIOSENSING, IN THE DETECTION OF SYMPATHETIC NERVOUS SYSTEM ACTIVITY IN OPIOID WITHDRAWAL, PEDIATRICS, BUSINESS DEVELOPMENT, AND INTELLECTUAL PROPERTY. OUR ACADEMIC PARTNERS HAVE BROAD EXPERIENCE IN NOVEL BIOSENSOR DEVELOPMENT.
$55.0k
2/18/21
Not listed
WIRELESS WITHDRAWAL DETECTION AND MONITORING SYSTEM FOR NEONATAL ABSTINENCE SYNDROME.
$225.0k
6/23/20